New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine`s Bavituximab With Radiation in a Lethal Brain Cancer Model
Posted on: 11/10/2009
New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Cancer Model
- Treatment in Combination with Radiation Doubled Survival Time and Produced Long-Term Cures in Lethal Brain Cancer Model -
November 10, 2009: 09:30 AM ET
TUSTIN, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company’s lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures. The study also provides further evidence that the anti-cancer activity of bavituximab and other PS-targeting antibodies reflects multiple novel mechanisms. Bavituximab is currently in Phase II clinical trials for the treatment of advanced breast cancer and advanced lung cancer. The new study is available in the current on-line edition of Clinical Cancer Research(1).
"This important new study provides additional scientific evidence that PS-targeting antibodies, including bavituximab, employ multiple novel mechanisms to mobilize the immune system to combat cancer and that these mechanisms are enhanced by concurrent radiation therapy," said Steven W. King, president and CEO of Peregrine. "The potent anti-tumor effects observed in this study, which used an extremely challenging preclinical model of brain cancer, are very impressive. These results provide a strong rationale for conducting future clinical trials of bavituximab in combination with radiation for the treatment of glioblastoma and other brain cancers."
The new study was designed to assess whether treatment with an antibody equivalent of bavituximab combined with radiotherapy can suppress tumor growth in a model of glioblastoma, the deadliest form of brain cancer. It used an especially aggressive tumor line that behaves very much like glioblastoma when injected into the brains of test animals. Results showed that the combination of a bavituximab equivalent and radiotherapy more than doubled the median survival time of test animals and 13% were rendered disease free, an unexpected outcome with this type of tumor. The combination treatment was significantly superior to either radiotherapy or treatment with the bavituximab equivalent alone.
The study authors also assessed the mechanisms of the observed anti-tumor effects. Analysis showed that radiation induced PS exposure on tumor blood vessels and enhanced the ability of the bavituximab equivalent to mobilize immune system monocyte and macrophage cells to attack the tumor blood vessels. In addition, the authors showed that the bavituximab equivalent enhanced the ability of the immune system to generate cytotoxic T cells specific to the brain cancer cells used in the studies. These immune cells were able to prevent the growth of cancer cells that had infiltrated throughout the normal brain. Treated animals that became cancer-free were immune when subsequently re-challenged with these normally deadly brain tumor cells.
Dr. Philip Thorpe, professor of pharmacology at UT Southwestern Medical Center and an author of the new study commented, "Scientists have long been perplexed about the fact that many tumors seem to be able to evade the immune system, making themselves invisible to immune recognition and attack. The studies reported in this new paper confirm our prior observations that tumor cells conceal themselves by flipping PS from inside the cells to their outer surface. This exposed PS sends what is essentially an "all clear" signal to the immune system, allowing the tumor to continue to grow and spread. PS-targeting antibodies such as bavituximab mask the exposed PS and enable the immune cells to recognize the cancer cells as foreign, mobilizing immune system defenses to attack the tumor and inhibit its growth. Bavituximab has already demonstrated encouraging anti-tumor activity in multiple human clinical trials, and we believe the novel mechanisms elucidated in these new studies indicate that it may also prove to be an effective new agent against glioblastoma."
Bavituximab is being tested in combination with chemotherapy in Phase II trials in advanced lung cancer and advanced breast cancer. Interim results in these trials have been encouraging, with objective tumor response rates that compare favorably to chemotherapy alone.
(1) Antiphosphatidylserine Antibody Combined with Irradiation Damages Tumor Blood Vessels and Induces Tumor Immunity in a Rat Model of Glioblastoma, Jin He, Yi Yin, Troy A. Luster, Linda Watkins, and Philip E. Thorpe, Clin Cancer Res1078-0432. CCR-09-1499; Published OnlineFirst November 3, 2009, doi:10.1158/1078-0432.CCR-09-1499
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and CotaraÂ®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that that the results of future clinical studies will not correlate or be consistent with the results of the completed preclinical studies and the risk that the company will experience delays or difficulties in enrolling patients in any planned future clinical studies. Factors that could cause actual results to differ materially or otherwise adversely impact the company’s ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
GendeLLindheim BioCom Partners
email@example.com Barbara Lindheim
(800) 987-8256 (212) 918-4650
SOURCE Peregrine Pharmaceuticals, Inc.
Click HERE to return to brain tumor news headlines